RNS Number : 4146L
ValiRx PLC
22 April 2024

**ValiRx plc**

("**ValiRx**" or the "**Company**")

**Directorate Changes**

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that, further to the announcements of 29 February and 19 March 2024, the Company has appointed Martin Gouldstone and Adrian de Courcey as Non-executive Directors with immediate effect, following completion of standard regulatory due diligence. In addition, Ray Horn has been appointed as a Board observer.

**Director Appointments**

*Adrian de Courcey*

Adrian de Courcey is a business executive with experience in both corporate and entrepreneurial environments in the UK and internationally. He began his career with KPMG and held strategy roles with Shell and Johnson & Johnson, with experience within the SME sector and built a transportation business. Adrian graduated from the University of Warwick and obtained an MBA from the University of Cambridge in 2020.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Adrian Michael Patrick de Courcey (aged 46):

| **Current Directorships** | **Previous Directorships held in the past five years** |
|---|---|
| Inishbofin Holdings Limited | Leofric Biomass Limited |
| Mike De Courcey Travel Limited[1] | West Midlands Transport Information Services Limited[2] |
| Tydfil Training Consortium Limited | |

[1] Adrian de Courcey was appointed as a director of Mike De Courcey Travel Limited on 1 July 2006. On 3 August 2021 the company was placed in a creditors voluntary liquidation. The liquidation process is ongoing.

[2] Adrian de Courcey was appointed as a director of West Midlands Transport Information Services Limited on 5 October 2011. On 21 September 2018 the company appointed a voluntary liquidator to conduct a members voluntary liquidation. The Company was dissolved 30 November 2021 with no creditor shortfall.

Adrian de Courcey holds 871,036 ordinary shares and 22,955 warrants over new ordinary shares in the Company.

There is no further information regarding Adrian de Courcey required to be disclosed under the AIM Rules.

*Martin Gouldstone*

Martin is currently CEO of Oncimmune Holdings plc and has 30 years of corporate finance and business development experience in contract research organisations, healthcare and pharmaceutical sectors. Previously, Martin was a Global Senior Vice President of Business Development at Owkin, Inc., where he managed the commercial teams in the USA and Europe and led new strategic research partnerships. More recently, Martin was Chief Business Officer at Sensyne Health; Global Senior Vice President and Head of Capital Solutions for Syneos Health; Chief Business Officer at BenevolentAI.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Martin John Gouldstone (aged 57):

| **Current Directorships** | **Previous Directorships held in the past five years** |
|---|---|
| hVIVO PLC (previously Open Orphan PLC) | Orthopaedic Research UK |
| Novara Therapeutics Limited | |
| Oncimmune Holdings PLC | |
| Sempiternum Ltd | |

Martin Gouldstone does not hold any ordinary shares or warrants over new ordinary shares in the Company.

There is no further information regarding Martin Gouldstone required to be disclosed under the AIM Rules.

**Additional Updates**

Further to the announcement of 4 March 2024, in the interest of ensuring a proportionate number of non-executive directors following today's appointments and taking into account the Company's size, Luke Cairns has advised, and the Company has agreed, that he will not be joining the board as a non-executive director at this time.

Ray Horn has been appointed as a Board observer with immediate effect.

**Kevin Cox, Chairman commented:** *"I am pleased that Adrian and Martin have joined the Board of ValiRx as the first step towards establishing a new management team. I look forward to their participation and providing commercial expertise to help guide the Company. I would also like to thank Luke for his time and efforts in working with us during this time of transition."*

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

| | |
|---|---|
| **ValiRx plc**<br><br>Dr Suzanne Dilly, CEO | **Tel: +44 (0) 2476 796496**<br>**www.valirx.com**<br>Suzanne.Dilly@valirx.com |
| **V Formation (Public Relations)**<br><br>Lucy Wharton - Senior PR Executive<br>Sue Carr - Director | **+44 (0) 115 787 0206**<br>www.vformation.biz<br><br>lucy@vformation.biz<br>sue@vformation.biz |
| **Cairn Financial Advisers LLP (Nominated Adviser)**<br><br>Liam Murray/Jo Turner/Ludovico Lazzaretti | **Tel: +44 (0) 20 7213 0880** |
| **Shard Capital Partners LLP (Sole Broker)**<br><br>Damon Heath | **Tel: +44 (0) 20 7186 9000** |

**Notes for Editors**

**About ValiRx**

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAEASLFALSLEFA